Not provided
Not provided
Not provided
Not provided
This study was terminated due to sponsor de-activation of all programs associated with RP-3500 (camonsertib).
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Repare Therapeutics | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This is an open-label, multicenter, phase Ib/II study of the combination of RP-3500 and olaparib in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) patients with DDR deficiencies.
The Phase Ib part of the trial will seek to assess the Maximum Tolerated Dose (MTD) of camonsertib (RP-3500) in combination with olaparib. Given the potential overlapping toxicities of RP-3500 and olaparib, a keyboard phase I design, a novel Bayesian method that typically underestimates the MTD,61 will be employed. The target toxicity is 30% with an equivalence interval between 25-33% of patients. With an anticipated 3 dose levels (DL) and an option for a DL-1, up to 18 patients may be required to determine the MTD. A maximum of 12 patients will be treated at a DL.
The first 5 patients treated at the previous DL1 (camonsertib 40mg daily and olaparib 100mg two times a day (BID) dosing 3 days per week) determined that this dosing strategy may not be appropriate for R/R CLL patients and reduced dosing may be necessary to increase safety of the combination therapy. Therefore, the newly proposed DLs will seek to enroll an additional 18 patients.
After completion of the phase Ib portion and assignment of the recommended phase 2 dose (RP2D), continuous enrollment of patients may commence into the phase II dose expansion portion. All patients enrolled at the RP2D during the phase Ib dose-escalation portion of the trial can be carried over into the phase II analysis. The maximum number of patients that can be carried over from the dose escalation to the dose-expansion portion is 12.
The phase II dose expansion will consist of two separate cohorts of subjects: an enrichment cohort and a cohort for all other eligible subjects. All subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation. Eight subjects will be enrolled into the enrichment cohort and 16 will be enrolled into the second cohort for a total phase II cohort of 24 patients.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Phase Ib: Dose Level -1 | Experimental | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 40mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. |
|
| Phase Ib: Dose Level 1 | Experimental | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 50mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. |
|
| Phase Ib: Dose Level 2 | Experimental | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. |
|
| Phase Ib: Dose Level 3 | Experimental | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 150mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. |
|
| Phase II: Dose Expansion Enrichment Cohort |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RP-3500 | Drug | RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Maximum Tolerated Dose (MTD) of Camonsertib (RP-3500) in Combination With Olaparib | This outcome will report the number of patients who experienced a Dose-Limiting Toxicity (DLT) in Phase Ib Dose Level 1, Phase Ib Dose Level 2, Phase Ib Dose Level 3, and Phase Ib Dose Level -1 during the DLT window (Cycle 1 Day 1 to Cycle 1 Day 21). A keyboard phase I design was employed; the target toxicity was 30% with an equivalence interval between 25-33% of patients. The first 5 patients were treated at DL-1 (camonsertib 40mg daily and olaparib 100mg BID dosing 3 days per week). | up to 28 days after initiation of study drug |
| Overall Response | This outcome will assess the overall responseof combination RP-3500 and olaparib. Overall response is defined by the count of subjects achieving any confirmed partial (PR) and complete response (CR) as assessed by 2018 International Working Group on Chronic Lymphocytic Leukemia (iwCLL) response criteria. Subjects without a baseline/screening tumor assessment or at least one on-treatment assessment will be considered non-responders. | up to 85 Days after initiation of study drug |
| Measure | Description | Time Frame |
|---|---|---|
| Adverse Events (AE) by Grade | This outcome measure will assess the safety and tolerability of RP-3500 and olaparib. The severity of AEs was assessed using CTCAE v5.0 criteria, a 1-5 scale with higher numbers indicating greater severity. Grade 1 indicates "mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated" and Grade 5 indicates "death related to AE". The severity of adverse hematologic adverse events was assessed using the 2018 IWCLL grading scale. Grade 0 indicates "≤10% decrease in platelets (PLT) or hemoglobin (Hb) from baseline and ≥2 absolute neutrophil count (ANC)" and Grade 4 indicates "≥75% decrease in PLT or Hb from baseline and <0.5 ANC" This outcome measure will report the count of participants who experienced each AE grade. Subjects were monitored for adverse events from the start of treatment until 28 days after the last dose of the study drug. |
Not provided
Inclusion Criteria:
Diagnosis of Chronic lymphocytic leukemia (CLL) according to the National Cancer Institute International Workshop on Chronic Lymphocytic Leukemia (NCI/IWCLL), criteria.
--This includes previous documentation of:
Biopsy-proven small lymphocytic lymphoma/CLL
OR
Diagnosis of CLL according to the NCI/IWCLL criteria as evidenced by all of the following:
Peripheral blood monoclonal B cell population of greater than 5x109/L
Immunophenotype consistent with CLL defined as:
Negative Fluorescence in situ hybridization (FISH) analysis for t(11;14)(IgH/CCND1) on peripheral blood or tissue biopsy (e.g. marrow aspirate), or negative immunohistochemical stains for cyclin D1 on involved tissue biopsy (e.g. marrow aspirate or lymph node biopsy).
Repeat testing of somatic mutations and FISH analysis must be performed by a Clinical Laboratory Improvement Amendments (CLIA) certified laboratory after progression is noted from most recent line of therapy and within 6 months of screening. Primary CLL cells must harbor one of these abnormalities:
Relapsed or refractory after at least 2 prior lines of therapy, and in the opinion of the treating Investigator are either not eligible for other approved therapies or no approved therapies are expected to have sustained therapeutic benefit.
Patient in need of treatment or change in treatment per iwCLL criteria.
--Patients on Bruton tyrosine kinase (BTK), Phosphoinositide 3-kinase inhibitor (PI3K) or B-cell lymphoma 2 (BCL2) inhibitors may enroll without meeting iwCLL criteria for treatment as long as there is clinical evidence of progression (i.e. increasing lymphocytosis, worsening anemia/thrombocytopenia attributable to CLL disease progression, increasing lymphadenopathy, or worsening patient symptoms) and require change in treatment at the discretion of the treating provider. Patients must still meet all other inclusion/exclusion criteria for enrollment including appropriate washout periods (5.2.2) and relapsed disease after 2 prior lines of therapy with no other approved therapies that are expected to have sustained therapeutic benefit (5.1.3).
Age ≥18 years
Eastern Cooperative Oncology Group (ECOG) performance status between 0-2
Expected life expectancy of at least 12 months per the investigator.
The following laboratory or clinical values obtained ≤ 42 days prior to enrollment:
Absolute neutrophil count ≥1000/µL (G-CSF support is allowed) unless documented bone marrow involvement of CLL
Platelets of ≥50K/µL unless documented bone marrow involvement of CLL
Creatinine Clearance (CrCl) ≥45 mL/minute as measured by a 24 hour urine collection or calculated by the Cockcroft-Gault Formula
Total bilirubin ≤ 1.5 x institutional upper limit of normal (ULN) unless due to Gilbert's disease. For those patients with previous history of Gilbert's disease, a direct bilirubin should be performed and must be <1.5mg/dL.
SGOT (AST)/SGPT (ALT) ≤3.0 x the institutional ULN
Time from the start of the Q wave to the end of the T wave (QT) corrected for heart rate by Fridericia's cube root formula (QTcF) ≤470 msec
Pulse oximetry reading of ≥90% on room air
Able to adhere to study visit schedule and other protocol requirements
Patients must be able to swallow capsules
Patients must be able to receive xanthine oxidase inhibitor and/or rasburicase for tumor lysis syndrome prophylaxis.
Patients with a history of hepatitis B (surface antigen or core antibody-positive and polymerase chain reaction (PCR) positive) must take lamivudine or equivalent drug during study therapy and for one year after completion of all therapy. Patients on IVIG who are core antibody-positive but PCR negative are not mandated to take prophylaxis.
Patients who are HIV (human immunodeficiency virus) positive are eligible under the following circumstances:
Recovery to baseline or ≤ Grade 1 CTCAE v5.0 from toxicities related to any prior cancer therapy, unless considered clinically not significant by the treating investigator.
Female patients capable of reproduction or males who have partners capable of reproduction must agree to the use of an effective contraceptive method during the course of the study and for 6 months following the completion of their last treatment.
Females of childbearing potential must have a negative serum β-Hcg pregnancy test result within 3 days of the first study dose. Female patients who are surgically sterilized or who are >45 years old and have not experienced menses for >2 years may have β-Hcg pregnancy test waived.
Exclusion Criteria:
Patients who are currently receiving any other investigational drug. Patients who are or have received therapies for the prevention, treatment or management of Corona Virus 19 (COVID-19) under the Food and Drug Administration (FDA) emergency use authorization are allowed to enroll.
Patients who have received:
Radiation or chemotherapy ≤2 weeks prior to registration.
Immunotherapy or targeted therapy ≤2 weeks prior to registration.
---Patients currently on BCR pathway antagonists (i.e. BTK and PI3K inhibitors, etc) require a 2 day wash out period prior to starting combination therapy with RP-3500 and olaparib as these subjects progress quickly after treatment discontinuation.
Strong CYP3A inhibitors or inducers, p-glycoprotein inhibitors, or BCRP inhibitors within five half-lives or 14 days of registration, whichever is shorter (See Appendix 5).
Prior ATR inhibitor use, but prior PARP inhibitor use for any reason is allowed on study.
Major surgery 4 weeks prior to C1D1 or who have not fully recovered from major surgery.
Evidence of active Richter's Transformation
Disease states requiring steroids (e.g. adrenal insufficiency, autoimmune conditions) are allowed as long as the steroid dose is ≤10mg of prednisone or equivalent dose of another steroid. Steroids premedications to prevent iodine contrast allergy for CT scans are allowed.
Patients who have undergone autologous stem cell transplant ≤4 weeks or allogeneic stem cell transplant ≤12 weeks prior to cycle 1 day 1 or have active graft-versus-host disease are excluded.
Patients who have active, clinically significant hepatic impairment (≥ moderate hepatic impairment according to the NCI/Child-Pugh classification)
Prior history of another malignancy except for the following:
Patients with active known central nervous system (CNS) involvement of CLL. Patients with a history of CNS CLL now in remission are eligible for the trial.
Patients with uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, extensive bilateral interstitial lung disease, unstable angina pectoris, or psychiatric illness/social situations that would limit compliance with study requirements.
--Patients with a history of pneumonitis or pulmonary disease that could predispose them to development of Interstitial lung disease (ILD) and/or underlying respiratory conditions should be excluded.
Known prior severe hypersensitivity to RP-3500, olaparib, or any component in its formulations (NCI CTCAE v5.0 Grade ≥ 3).
Female patients who are pregnant or actively breast feeding
Patients with conditions significantly affecting gastrointestinal function including, but not limited to:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Boyu Hu, MD | Huntsman Cancer Institute | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Huntsman Cancer Institute at the University of Utah | Salt Lake City | Utah | 84112 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Phase Ib: Dose Level -1 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 40mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| FG001 | Phase Ib: Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 50mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| FG002 | Phase Ib: Dose Level 2 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| FG003 | Phase Ib: Dose Level 3 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 150mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| FG004 | Phase II: Dose Expansion Enrichment Cohort | Subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| FG005 | Phase II: Dose Expansion Eligible Subjects Cohort | Cohort will include all other eligible subjects for Dose Expansion. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. |
| FG006 | Phase Ib (Prior to Aug2023 Amendment): Original Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Before the Aug2023 amendment, patients enrolled at Dose Level 1 received RP-3500 40mg daily and olaparib 100mg BID. Both drugs were given with intermittent dosing of 3 days per week and each cycle was 28 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
No participants were enrolled in Phase Ib: dose level -1, Phase Ib: dose level 1, Phase Ib: dose level 2, Phase Ib: dose level 3, Phase II: Dose Expansion Enrichment, or Phase II: Dose Expansion.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Phase Ib: Dose Level -1 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 40mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Maximum Tolerated Dose (MTD) of Camonsertib (RP-3500) in Combination With Olaparib | This outcome will report the number of patients who experienced a Dose-Limiting Toxicity (DLT) in Phase Ib Dose Level 1, Phase Ib Dose Level 2, Phase Ib Dose Level 3, and Phase Ib Dose Level -1 during the DLT window (Cycle 1 Day 1 to Cycle 1 Day 21). A keyboard phase I design was employed; the target toxicity was 30% with an equivalence interval between 25-33% of patients. The first 5 patients were treated at DL-1 (camonsertib 40mg daily and olaparib 100mg BID dosing 3 days per week). | No participants were enrolled in the Phase Ib: Dose Level -1, 1, 2, and 3 Cohorts or in the Phase II: Dose Expansion Enrichment or Dose Expansion Cohorts. | Posted | Count of Participants | Participants | up to 28 days after initiation of study drug |
|
Subjects were monitored for adverse events from the start of treatment until 28 days after the last dose of the study drug (up to 113 days after initiation of study drug). Subjects were monitored for survival for up to 21 months after study registration.
No participants were enrolled in the Phase Ib: Dose Level 1, 2, and 3 Cohorts or in the Phase II: Dose Expansion Enrichment or Dose Expansion Cohorts.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Phase Ib: Dose Level -1 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 40mg of RP-3500 daily and 100mg Olaparib BID. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| IIT Data Management Team | Research Compliance Office, Huntsman Cancer Institute | 801-213-6215 | IITDataManagement@hci.utah.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Aug 28, 2023 | Feb 13, 2025 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015451 | Leukemia, Lymphocytic, Chronic, B-Cell |
| ID | Term |
|---|---|
| D015448 | Leukemia, B-Cell |
| D007945 | Leukemia, Lymphoid |
| D007938 | Leukemia |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
| ID | Term |
|---|---|
| C531550 | olaparib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Experimental |
Subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation. |
|
| Phase II: Dose Expansion Eligible Subjects Cohort | Experimental | Cohort will include all other eligible subjects for Dose Expansion. |
|
| Phase Ib (prior to Aug2023 amendment): Original Dose Level 1 | Experimental | To assess the MTD of RP-3500 in combination with olaparib. Before the Aug2023 amendment, patients enrolled at Dose Level 1 received RP-3500 40mg daily and olaparib 100mg BID. Both drugs were given with intermittent dosing of 3 days per week and each cycle was 28 days. |
|
| Olaparib | Drug | Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
|
| up to 28 days after the last dose of study treatment (up to 113 days after initiation of study drug) |
| Progression-free Survival (PFS) | Progression-free survival (PFS) as defined as the time from study drug initiation to the time documented disease progression (as assessed by 2018 iwCLL criteria) or death from any cause. Patients were followed for PFS until progression of disease was noted or death, whichever occurred first. This outcome will report the median PFS with 95% confidence intervals. | up to 15 months from initiation of study treatment |
| Overall Survival (OS) | This outcome will assess OS as defined as the time between treatment initiation and death of any cause. Subjects were followed for OS from the initiation of therapy until death from any cause or until the study was terminated. Subjects lost to follow-up or refused follow-up were censored at the time of the last known follow-up. This outcome will report the median OS with 95% confidence intervals. | up to 21 months after study registration |
| Duration of Response (DoR) as Defined as the Interval of Time From the Date of Initial Documented Response (PR or Better as Per 2018 iwCLL Criteria for Response) to the Time of Progression. | DoR is defined as the interval of time from the date of the initial documented response (PR or better as per 2018 iwCLL criteria for response) to the time of progression. Patients would be followed for DoR from the date of the initial documented response until progression of disease was noted or death, whichever occurred first. This outcome would have reported the median DoR with 95% confidence intervals. | up to 21 months after initiation of study treatment. |
| BG001 | Phase Ib: Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 50mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| BG002 | Phase Ib: Dose Level 2 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| BG003 | Phase Ib: Dose Level 3 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 150mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| BG004 | Phase II: Dose Expansion Enrichment Cohort | Subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| BG005 | Phase II: Dose Expansion Eligible Subjects Cohort | Cohort will include all other eligible subjects for Dose Expansion. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. |
| BG006 | Phase Ib (Prior to Aug2023 Amendment): Original Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Before the Aug2023 amendment, patients enrolled at Dose Level 1 received RP-3500 40mg daily and olaparib 100mg BID. Both drugs were given with intermittent dosing of 3 days per week and each cycle was 28 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| BG007 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG001 | Phase Ib: Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 50mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| OG002 | Phase Ib: Dose Level 2 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 100mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| OG003 | Phase Ib: Dose Level 3 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive RP-3500 80mg daily and olaparib 150mg BID. Both drugs are given with intermittent dosing of 2 days per week and each cycle is 21 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| OG004 | Phase II: Dose Expansion Enrichment Cohort | Subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
| OG005 | Phase II: Dose Expansion Eligible Subjects Cohort | Cohort will include all other eligible subjects for Dose Expansion. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. |
| OG006 | Phase Ib (Prior to Aug2023 Amendment): Original Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Before the Aug2023 amendment, patients enrolled at Dose Level 1 received RP-3500 40mg daily and olaparib 100mg BID. Both drugs were given with intermittent dosing of 3 days per week and each cycle was 28 days. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. |
|
|
|
| Primary | Overall Response | This outcome will assess the overall responseof combination RP-3500 and olaparib. Overall response is defined by the count of subjects achieving any confirmed partial (PR) and complete response (CR) as assessed by 2018 International Working Group on Chronic Lymphocytic Leukemia (iwCLL) response criteria. Subjects without a baseline/screening tumor assessment or at least one on-treatment assessment will be considered non-responders. | No participants were enrolled in the Phase Ib: Dose Level -1, 1, 2, and 3 Cohorts or in the Phase II: Dose Expansion Enrichment or Dose Expansion Cohorts. | Posted | Count of Participants | Participants | up to 85 Days after initiation of study drug |
|
|
|
| Secondary | Adverse Events (AE) by Grade | This outcome measure will assess the safety and tolerability of RP-3500 and olaparib. The severity of AEs was assessed using CTCAE v5.0 criteria, a 1-5 scale with higher numbers indicating greater severity. Grade 1 indicates "mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated" and Grade 5 indicates "death related to AE". The severity of adverse hematologic adverse events was assessed using the 2018 IWCLL grading scale. Grade 0 indicates "≤10% decrease in platelets (PLT) or hemoglobin (Hb) from baseline and ≥2 absolute neutrophil count (ANC)" and Grade 4 indicates "≥75% decrease in PLT or Hb from baseline and <0.5 ANC" This outcome measure will report the count of participants who experienced each AE grade. Subjects were monitored for adverse events from the start of treatment until 28 days after the last dose of the study drug. | No participants were enrolled in the Phase Ib: Dose Level -1, 1, 2, and 3 Cohorts or in the Phase II: Dose Expansion Enrichment or Dose Expansion Cohorts. | Posted | Count of Participants | Participants | up to 28 days after the last dose of study treatment (up to 113 days after initiation of study drug) |
|
|
|
| Secondary | Progression-free Survival (PFS) | Progression-free survival (PFS) as defined as the time from study drug initiation to the time documented disease progression (as assessed by 2018 iwCLL criteria) or death from any cause. Patients were followed for PFS until progression of disease was noted or death, whichever occurred first. This outcome will report the median PFS with 95% confidence intervals. | No participants were enrolled in the Phase Ib: Dose Level 1, 2, and 3 Cohorts or in the Phase II: Dose Expansion Enrichment or Dose Expansion Cohorts. | Posted | Median | 95% Confidence Interval | months | up to 15 months from initiation of study treatment |
|
|
|
| Secondary | Overall Survival (OS) | This outcome will assess OS as defined as the time between treatment initiation and death of any cause. Subjects were followed for OS from the initiation of therapy until death from any cause or until the study was terminated. Subjects lost to follow-up or refused follow-up were censored at the time of the last known follow-up. This outcome will report the median OS with 95% confidence intervals. | No participants were enrolled in the Phase Ib: Dose Level -1, 1, 2, and 3 Cohorts or in the Phase II: Dose Expansion Enrichment or Dose Expansion Cohorts. | Posted | Median | 95% Confidence Interval | months | up to 21 months after study registration |
|
|
|
| Secondary | Duration of Response (DoR) as Defined as the Interval of Time From the Date of Initial Documented Response (PR or Better as Per 2018 iwCLL Criteria for Response) to the Time of Progression. | DoR is defined as the interval of time from the date of the initial documented response (PR or better as per 2018 iwCLL criteria for response) to the time of progression. Patients would be followed for DoR from the date of the initial documented response until progression of disease was noted or death, whichever occurred first. This outcome would have reported the median DoR with 95% confidence intervals. | No participants had an initial documented response. | Posted | up to 21 months after initiation of study treatment. |
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | Phase Ib: Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 50mg of RP-3500 daily and 100mg Olaparib BID. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG002 | Phase Ib: Dose Level 2 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 80mg of RP-3500 daily and 100mg Olaparib BID. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG003 | Phase Ib: Dose Level 3 | To assess the MTD of RP-3500 in combination with olaparib. Patients will receive 80mg of RP-3500 daily and 150mg Olaparib BID. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG004 | Phase II: Dose Expansion Enrichment Cohort | Subjects enrolled into the enrichment cohort must have a del(11q) and/or ATM mutation. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG005 | Phase II: Dose Expansion Eligible Subjects Cohort | Cohort will include all other eligible subjects for Dose Expansion. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. | 0 | 0 | 0 | 0 | 0 | 0 |
| EG006 | Phase Ib (Prior to Aug2023 Amendment): Original Dose Level 1 | To assess the MTD of RP-3500 in combination with olaparib. Before the Aug2023 amendment, patients enrolled at Dose Level 1 received RP-3500 40mg daily and olaparib 100mg BID. Both drugs were given with intermittent dosing of 3 days per week and each cycle was 28 days. RP-3500: RP-3500 is a highly potent and selective Ataxia telangiectasia and Rad3 related inhibitor (ATRi) and has demonstrated significant preclinical activity. Olaparib: Olaparib is an oral poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) that inhibits PARP's function by competitively binding to the Nicotinamide adenine dinucleotide (NAD+) binding site, which PARP requires as a cofactor to operate. | 2 | 5 | 2 | 5 | 5 | 5 |
| Febrile neutropenia | Blood and lymphatic system disorders | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | Systematic Assessment |
|
| Anorexia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Arthritis | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Bruising | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Creatinine increased | Investigations | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | Systematic Assessment |
|
| Dizziness | Nervous system disorders | Systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | Systematic Assessment |
|
| Edema limbs | General disorders | Systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | Systematic Assessment |
|
| Fatigue | General disorders | Systematic Assessment |
|
| Generalized muscle weakness | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Hypercalcemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypocalcemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypokalemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypomagnesemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Hypophosphatemia | Metabolism and nutrition disorders | Systematic Assessment |
|
| Lung infection | Infections and infestations | Systematic Assessment |
|
| Musculoskeletal and connective tissue disorder - Other, specify | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Neutrophil count decreased | Investigations | Systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Platelet count decreased | Investigations | Systematic Assessment |
|
| Sepsis | Infections and infestations | Systematic Assessment |
|
| Skin and subcutaneous tissue disorders - Other, specify | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Sore throat | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
|
| Tinnitus | Ear and labyrinth disorders | Systematic Assessment |
|
| Urinary tract infection | Infections and infestations | Systematic Assessment |
|
| Weight loss | Investigations | Systematic Assessment |
|
Not provided
Not provided
Not provided
| D009369 |
| Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| CTCAE Grade 3 |
|
| CTCAE Grade 4 |
|
| CTCAE Grade 5 |
|
| iwCLL Hematologic Grade 0 |
|
| iwCLL Hematologic Grade 1 |
|
| iwCLL Hematologic Grade 2 |
|
| iwCLL Hematologic Grade 3 |
|
| iwCLL Hematologic Grade 4 |
|